Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Effects One-for-Four Reverse Stock Split

NEW YORK (GenomeWeb) – BG Medicine said on Wednesday that it has effected a one-for-four reverse stock split to remain listed on the Nasdaq.

The reverse split increases the share price of the company's stock above the minimum $1 bid price to continue listing on the Nasdaq Capital Market. The firm's shares opened at $1.61 per share today after closing at $.43 per share on Wednesday. In early morning trading, the stock rose to $2 per share.

The stock split reduced the number of BG Medicine's common shares outstanding to about 8.6 million shares from about 34.6 million shares.

The Waltham, Massachusetts-based company was warned by Nasdaq in September that it was not in compliance with the $1 minimum bid requirement and could face delisting action. BG Medicine was also warned by Nasdaq in November that it was not in compliance with a listing requirement calling for a minimum $2.5 million in stockholders' equity to continue listing on the exchange.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more